Literature DB >> 18058397

The impact of illicit drug use and substance abuse treatment on adherence to HAART.

P L Hicks1, K P Mulvey, G Chander, J A Fleishman, J S Josephs, P T Korthuis, J Hellinger, P Gaist, K A Gebo.   

Abstract

High levels of adherence to highly active antiretroviral therapy (HAART) are essential for virologic suppression and longer survival in patients with HIV. We examined the effects of substance abuse treatment, current versus former substance use, and hazardous/binge drinking on adherence to HAART. During 2003, 659 HIV patients on HAART in primary care were interviewed. Adherence was defined as > or =95% adherence to all antiretroviral medications. Current substance users used illicit drugs and/or hazardous/binge drinking within the past six months, while former users had not used substances for at least six months. Logistic regression analyses of adherence to HAART included demographic, clinical and substance abuse variables. Sixty-seven percent of the sample reported 95% adherence or greater. However, current users (60%) were significantly less likely to be adherent than former (68%) or never users (77%). In multivariate analysis, former users in substance abuse treatment were as adherent to HAART as never users (Adjusted Odds Ratio (AOR)=0.82; p>0.5). In contrast, former users who had not received recent substance abuse treatment were significantly less adherent than never users (AOR=0.61; p=0.05). Current substance users were significantly less adherent than never users, regardless of substance abuse treatment (p<0.01). Substance abuse treatment interacts with current versus former drug use status to affect adherence to HAART. Substance abuse treatment may improve HAART adherence for former substance users.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18058397      PMCID: PMC4126518          DOI: 10.1080/09540120701351888

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  21 in total

1.  Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens.

Authors:  A L Gifford; J E Bormann; M J Shively; B C Wright; D D Richman; S A Bozzette
Journal:  J Acquir Immune Defic Syndr       Date:  2000-04-15       Impact factor: 3.731

2.  Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes.

Authors:  A Moreno; M J Perez-Elías; J L Casado; V Muñoz; A Antela; F Dronda; E Navas; S Moreno
Journal:  AIDS       Date:  2001-05-25       Impact factor: 4.177

3.  Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.

Authors:  J P Moatti; M P Carrieri; B Spire; J A Gastaut; J P Cassuto; J Moreau
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

4.  Drug abuse, methadone treatment, and health services use among injection drug users with AIDS.

Authors:  U Sambamoorthi; L A Warner; S Crystal; J Walkup
Journal:  Drug Alcohol Depend       Date:  2000-07-01       Impact factor: 4.492

5.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

Authors:  D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

6.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

7.  Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy.

Authors:  K E Poundstone; R E Chaisson; R D Moore
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

8.  Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.

Authors:  G M Lucas; L W Cheever; R E Chaisson; R D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

9.  Problem drinking and medication adherence among persons with HIV infection.

Authors:  R L Cook; S M Sereika; S C Hunt; W C Woodward; J A Erlen; J Conigliaro
Journal:  J Gen Intern Med       Date:  2001-02       Impact factor: 5.128

10.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).

Authors:  M A Chesney; J R Ickovics; D B Chambers; A L Gifford; J Neidig; B Zwickl; A W Wu
Journal:  AIDS Care       Date:  2000-06
View more
  37 in total

1.  Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications.

Authors:  Noah C Godwin; James H Willig; Christa R Nevin; Hui-Yi Lin; Jeroan Allison; Kathy Gaddis; Jennifer Peterson; Michael S Saag; Michael J Mugavero; James L Raper
Journal:  Health Serv Res       Date:  2011-01-06       Impact factor: 3.402

2.  Correlates of sexual activity and sexually transmitted infections among human immunodeficiency virus-infected youth in the LEGACY cohort, United States, 2006.

Authors:  Rosanna W Setse; George K Siberry; Patti E Gravitt; William J Moss; Allison L Agwu; John T Wheeling; Beverly A Bohannon; Kenneth L Dominguez
Journal:  Pediatr Infect Dis J       Date:  2011-11       Impact factor: 2.129

3.  Proteomic Profiling of Exosomes Derived from Plasma of HIV-Infected Alcohol Drinkers and Cigarette Smokers.

Authors:  Sunitha Kodidela; Yujie Wang; Benjamin J Patters; Yuqing Gong; Namita Sinha; Sabina Ranjit; Kelli Gerth; Sanjana Haque; Theodore Cory; Carole McArthur; Anil Kumar; Jim Y Wan; Santosh Kumar
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-08       Impact factor: 4.147

4.  A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV.

Authors:  Brent A Moore; Marc I Rosen; Yan Wang; Jie Shen; Karen Ablondi; Anna Sullivan; Mario Guerrero; Lisa Siqueiros; Eric S Daar; Honghu Liu
Journal:  AIDS Behav       Date:  2015-06

5.  Cigarette smoking and drug use among a nationally representative sample of HIV-positive individuals.

Authors:  Lauren R Pacek; Paul T Harrell; Silvia S Martins
Journal:  Am J Addict       Date:  2014-07-25

6.  Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.

Authors:  Philip T Korthuis; Paula J Lum; Pamela Vergara-Rodriguez; Keith Ahamad; Evan Wood; Lynn E Kunkel; Neal L Oden; Robert Lindblad; James L Sorensen; Virgilio Arenas; Doan Ha; Raul N Mandler; Dennis McCarty
Journal:  Addiction       Date:  2017-02-08       Impact factor: 6.526

Review 7.  Challenges in managing HIV in people who use drugs.

Authors:  Adeeba Kamarulzaman; Frederick L Altice
Journal:  Curr Opin Infect Dis       Date:  2015-02       Impact factor: 4.915

8.  Provider-patient communication about adherence to anti-retroviral regimens differs by patient race and ethnicity.

Authors:  M Barton Laws; Yoojin Lee; William H Rogers; Mary Catherine Beach; Somnath Saha; P Todd Korthuis; Victoria Sharp; Jonathan Cohn; Richard Moore; Ira B Wilson
Journal:  AIDS Behav       Date:  2014-07

9.  Substance use and sexual risk behaviors in perinatally human immunodeficiency virus-exposed youth: roles of caregivers, peers and HIV status.

Authors:  Katherine S Elkington; Jose A Bauermeister; Elizabeth Brackis-Cott; Curtis Dolezal; Claude A Mellins
Journal:  J Adolesc Health       Date:  2009-03-29       Impact factor: 5.012

10.  HIV women's health: a study of gynecological healthcare service utilization in a U.S. urban clinic population.

Authors:  Monique A Tello; Hsin-Chieh Yeh; Jean M Keller; Mary C Beach; Jean R Anderson; Richard D Moore
Journal:  J Womens Health (Larchmt)       Date:  2008-12       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.